Figure 4
Figure 4. Pam2-ODN does not influence tumor burden. Quantitative PCR for TLR genes 4 hours after treatment with Pam2-ODN or PBS of (A) FBL3 cells or (B) MLE15 cells. (C) BrdU-positive FBL3 cells 24 hours after the indicated treatments. (D) Total FBL3 cells counts by hemacytometer 24 hours after treatment. (E) BrdU-positive FBL3 cells 24 hours after treatment when grown in coculture with MLE15 cells. (F) BrdU staining of FBL3 cells. Scale bar, 100 µm. (G) Live FBL3 cells determined by Trypan blue exclusion at the indicated time points after treatment. (H) Flow cytometry for GFP-positive cells in mouse blood after treatment with Pam2-ODN or PBS. All data represent ≥3 experiments. N = 4 mice per group. *P < .005, **P < .0001.

Pam2-ODN does not influence tumor burden. Quantitative PCR for TLR genes 4 hours after treatment with Pam2-ODN or PBS of (A) FBL3 cells or (B) MLE15 cells. (C) BrdU-positive FBL3 cells 24 hours after the indicated treatments. (D) Total FBL3 cells counts by hemacytometer 24 hours after treatment. (E) BrdU-positive FBL3 cells 24 hours after treatment when grown in coculture with MLE15 cells. (F) BrdU staining of FBL3 cells. Scale bar, 100 µm. (G) Live FBL3 cells determined by Trypan blue exclusion at the indicated time points after treatment. (H) Flow cytometry for GFP-positive cells in mouse blood after treatment with Pam2-ODN or PBS. All data represent ≥3 experiments. N = 4 mice per group. *P < .005, **P < .0001.

Close Modal

or Create an Account

Close Modal
Close Modal